Logo image of NURS.CA

HYDREIGHT TECHNOLOGIES INC (NURS.CA) Stock Fundamental Analysis

TSX-V:NURS - TSX Venture Exchange - CA44877L1013 - Common Stock - Currency: CAD

1.52  -0.29 (-16.02%)

Fundamental Rating

1

NURS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. NURS may be in some trouble as it scores bad on both profitability and health. NURS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NURS has reported negative net income.
In the past year NURS had a positive cash flow from operations.
NURS.CA Yearly Net Income VS EBIT VS OCF VS FCFNURS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -1M -2M -3M -4M -5M

1.2 Ratios

Industry RankSector Rank
ROA -46.48%
ROE N/A
ROIC N/A
ROA(3y)-135.09%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NURS.CA Yearly ROA, ROE, ROICNURS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin are not available for NURS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NURS.CA Yearly Profit, Operating, Gross MarginsNURS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

NURS does not have a ROIC to compare to the WACC, probably because it is not profitable.
NURS has more shares outstanding than it did 1 year ago.
There is no outstanding debt for NURS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NURS.CA Yearly Shares OutstandingNURS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
NURS.CA Yearly Total Debt VS Total AssetsNURS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 500K 1M 1.5M 2M 2.5M

2.2 Solvency

An Altman-Z score of 6.50 indicates that NURS is not in any danger for bankruptcy at the moment.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 6.5
ROIC/WACCN/A
WACC8.93%
NURS.CA Yearly LT Debt VS Equity VS FCFNURS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 -500K -1M -1.5M

2.3 Liquidity

NURS has a Current Ratio of 0.41. This is a bad value and indicates that NURS is not financially healthy enough and could expect problems in meeting its short term obligations.
NURS has a Quick Ratio of 0.41. This is a bad value and indicates that NURS is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.39
NURS.CA Yearly Current Assets VS Current LiabilitesNURS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

NURS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.19%, which is quite impressive.
The Revenue has grown by 169.54% in the past year. This is a very strong growth!
EPS 1Y (TTM)68.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.42%
Revenue 1Y (TTM)169.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.57%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NURS.CA Yearly Revenue VS EstimatesNURS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2M 4M 6M 8M 10M
NURS.CA Yearly EPS VS EstimatesNURS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NURS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NURS.CA Price Earnings VS Forward Price EarningsNURS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NURS.CA Per share dataNURS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NURS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYDREIGHT TECHNOLOGIES INC

TSX-V:NURS (2/10/2025, 7:00:00 PM)

1.52

-0.29 (-16.02%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-21 2024-11-21
Earnings (Next)04-28 2025-04-28
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.05%
Ins Owner ChangeN/A
Market Cap61.29M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.99
P/FCF N/A
P/OCF 163.1
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.01
OCFY0.61%
SpS0.38
BVpS-0.04
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.33%
FCFM N/A
ROA(3y)-135.09%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover5.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 559.62%
Cap/Sales 6.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.39
Altman-Z 6.5
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)11.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.42%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)169.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.87%
OCF growth 3YN/A
OCF growth 5YN/A